...
机译:Penta-Remcractory多发性骨髓瘤(mm)中的枢轴风暴研究(第2部分):与Penta-Remctory mm患者的口服塞里宁克斯加低剂量地塞米松的深和耐用响应
Mt Sinai Sch Med New York NY USA;
Univ Penn Abramson Canc Ctr Philadelphia PA 19104 USA;
Univ Athens Athens Greece;
Emory Univ Sch Med Dept Hematol &
Med Oncol Winship Canc Inst Atlanta GA USA;
Johns Hopkins Univ Sidney Kimmel Comprehens Canc Ctr Baltimore MD USA;
Univ Hosp Hotel Dieu Nantes France;
Univ Michigan Div Hematol Oncol Ann Arbor MI 48109 USA;
Icahn Sch Med Mt Sinai New York NY 10029 USA;
Mayo Clin Div Hematol Rochester MN USA;
Washington Univ Siteman Canc Ctr St Louis MO USA;
Univ N Carolina Chapel Hill NC 27515 USA;
Univ Hosp Heidelberg Dept Med 5 Heidelberg Germany;
Univ Hosp Tuebingen Dept Hematol Oncol &
Immunol Tubingen Germany;
Univ Hosp UZ Leuven Dept Hematol Leuven Belgium;
NYU Langone Hlth New York NY USA;
Vanderbilt Univ Med Ctr Dept Med Div Hematol &
Oncol Nashville TN USA;
Mayo Clin Scottsdale AZ USA;
Univ Miami Ctr Canc Miami FL USA;
Univ Alabama Birmingham Birmingham AL USA;
Yale Univ Sch Med Hematol New Haven CT USA;
Baylor Univ Dallas TX USA;
Univ Hosp Wurzburg Dept Internal Med 2 Wurzburg Germany;
Inst Jules Bordet Brussels Belgium;
Necker Childrens Hosp Paris France;
St Antoine Hosp Serv Hematol Clin &
Therapie Cellulaire Paris France;
Hop La Pitie Salpetriere Dept Hematol Paris France;
Massachusetts Gen Hosp Boston MA 02114 USA;
Univ Athens Sch Med Dept Clin Therapeut Athens Greece;
Univ Alabama Birmingham Vestavia AL USA;
Karyopharm Therapeut Newton MA USA;
Karyopharm Therapeut Newton MA USA;
Karyopharm Therapeut Newton MA USA;
Karyopharm Therapeut Newton MA USA;
Karyopharm Therapeut Newton MA USA;
Karyopharm Therapeut Newton MA USA;
Harvard Med Sch Dana Farber Canc Inst Dept Med Oncol Boston MA USA;
Mt Sinai Hosp New York NY 10029 USA;
机译:Penta-Remcractory多发性骨髓瘤(mm)中的枢轴风暴研究(第2部分):与Penta-Remctory mm患者的口服塞里宁克斯加低剂量地塞米松的深和耐用响应
机译:在先前暴露于蛋白酶体抑制剂和免疫调节药物的多发性骨髓瘤(mm)患者中,对塞里宁克斯,达拉姆人和Dexamethasome(SDD)的深度和耐用反应:SDD相1B研究结果
机译:Isatuximab加上氯胺和低剂量的地塞米松与氯胺和低剂量的地塞米松,患者复发和难治性多骨髓瘤(icaria-mm):一个随机的,多型,开放标签,第3期研究
机译:延长患者的延长后续研究,不符合口服梅酚和地塞米松治疗干细胞移植的患者
机译:Wilms的肿瘤蛋白1和癌症/睾丸抗原7在多发性骨髓瘤中的表达和免疫反应。
机译:MM-003的3期随机研究比较了pomalidomide联合小剂量地塞米松与大剂量地塞米松与大剂量地塞米松在复发/难治性多发性骨髓瘤中的作用以及先前治疗和反应深度对生存率的影响
机译:MM-003的3期随机研究比较了pomalidomide联合小剂量地塞米松与大剂量地塞米松与大剂量地塞米松治疗复发/难治性多发性骨髓瘤的疗效,以及MM-003中反应的深度对生存率的影响